Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Симптоматика, клиническое течение и лечение гиперактивности мочевого пузыря у женщин
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Мазо Е.Б., Кривобородов Г.Г. Гиперактивный мочевой пузырь. М.: Вече, 2003.
2. Abrams P, Cardozo L, Fall M et al. The standartisation of terminology in lower urinary tract function. Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21 (2): 167–78.
3. Cardozo L, Lisec M, Kuzmin I et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172 (5): 1919–24.
4. Cardozo L, Nagy G, Kiss L, Al-Shukri S. Solifenacin in the treatment of urgency symptoms of overactive bladder in a flexible dose, placebo controlled trial (the SUNRISE study). Int Urogynecol J 2006; 17 (suppl. 2): S052.
5. Chapple CR, Rechberger T, Al-Shukri S et al. YM-905 Study Group Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93 (3): 303–10.
6. Chapple C. The contemporary pharmacological management of overactive bladder BJOG. 2006; 113 (Suppl. 2): 19–28.
7. Hatanaka T, Ukai M, Ohtake A et al. In vitro tissue selectivity profile of solifenacine succinate (YM905) for urinary bladder over salivary gland in rats and monkeys. International Continence Society Meeting. Florence, Italy, 2003; Abstract 312.
8. Nabi G, Cody JD, Ellis G et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; 18 (4).
9. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20 (6): 327–36.
2. Abrams P, Cardozo L, Fall M et al. The standartisation of terminology in lower urinary tract function. Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21 (2): 167–78.
3. Cardozo L, Lisec M, Kuzmin I et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172 (5): 1919–24.
4. Cardozo L, Nagy G, Kiss L, Al-Shukri S. Solifenacin in the treatment of urgency symptoms of overactive bladder in a flexible dose, placebo controlled trial (the SUNRISE study). Int Urogynecol J 2006; 17 (suppl. 2): S052.
5. Chapple CR, Rechberger T, Al-Shukri S et al. YM-905 Study Group Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93 (3): 303–10.
6. Chapple C. The contemporary pharmacological management of overactive bladder BJOG. 2006; 113 (Suppl. 2): 19–28.
7. Hatanaka T, Ukai M, Ohtake A et al. In vitro tissue selectivity profile of solifenacine succinate (YM905) for urinary bladder over salivary gland in rats and monkeys. International Continence Society Meeting. Florence, Italy, 2003; Abstract 312.
8. Nabi G, Cody JD, Ellis G et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; 18 (4).
9. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20 (6): 327–36.
Авторы
С.Х.Аль-Шукри, И.В.Кузьмин
Кафедра урологии Санкт-Петербургского государственного медицинского университета
им. И.П.Павлова (зав. – проф. С.Х.Аль-Шукри)
Кафедра урологии Санкт-Петербургского государственного медицинского университета
им. И.П.Павлова (зав. – проф. С.Х.Аль-Шукри)
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.